Expression of MEF2D in Lung Adenocarcinoma and Its Correlation with Prognosis. (English)
In: Chinese Journal of Lung Cancer, Jg. 26 (2023-07-01), Heft 7, S. 538-544
Online
academicJournal
Zugriff:
Background and objective Myocyte enhancer factor 2D (MEF2D) can participate in the process of tumor lesions by regulating the transcription of oncogenes. In a previous study, MEF2D was demonstrated to enhance the proliferation and metastasis of lung adenocarcinoma cells A549 and H1299 by promoting the transcription of NUSAP1. The research aimed to explore the expression level and clinical significance of MEF2D in lung adenocarcinoma. Methods A total of 199 patients with lung adenocarcinoma were collected. Immunohistochemical staining was used to detect MEF2D expression levels in cancer and adjacent tissues. After the clinical and follow-up data were collated, the correlation between MEF2D expression level and clinical characteristics and prognosis of the patients was analyzed. Results In the lung adenocarcinoma, the high expression rate of MEF2D in cancer tissues was significantly higher than that in adjacent tissues (P<0.05). According to immunohistochemical score, MEF2D expression level in lung adenocarcinoma tissues was correlated with tumor differentiation, N stage, M stage and intrapulmonary metastasis (P<0.05). Kaplan-Meier analysis showed that patients with low MEF2D expression had significantly better prognosis than patients with high MEF2D expression (P<0.05). Cox multivariate analysis showed that MEF2D expression level, M stage, N stage and bone metastasis of lung cancer were independent risk factors for prognosis of lung adenocarcinoma patients. Conclussion MEF2D expression level is closely related to the metastasis of lung adenocarcinoma and other clinical characteristics, and can be used as an independent risk factor for the prognosis of patients with lung adenocarcinoma, which has the potential to be developed as a clinical diagnosis and treatment target of lung adeno-carcinoma. [ABSTRACT FROM AUTHOR]
Copyright of Chinese Journal of Lung Cancer is the property of Chinese Journal of Lung Cancer and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Expression of MEF2D in Lung Adenocarcinoma and Its Correlation with Prognosis. (English)
|
---|---|
Autor/in / Beteiligte Person: | Guangbin, YE ; Zhongwei, ZHANG ; Yanli, LI ; Li, GAO ; Wei, HUANG ; Bo, LING |
Link: | |
Zeitschrift: | Chinese Journal of Lung Cancer, Jg. 26 (2023-07-01), Heft 7, S. 538-544 |
Veröffentlichung: | 2023 |
Medientyp: | academicJournal |
ISSN: | 1009-3419 (print) |
DOI: | 10.3779/j.issn.1009-3419.2023.102.25 |
Schlagwort: |
|
Sonstiges: |
|